Slide 1: LD MicroCap Event
InfuSystem Holdings, Inc. Exhibit 99.1 LD MicroCap Event December 5, 2013 Eric K. Steen, CEO Jonathan P. Foster, CFO
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements contained in this release are forward-looking statements and are based on future expectations, plans and prospects for InfuSystem Holdings, Inc.’s (“InfuSystem”, “INFU”, “the Company”, “We”) business and operations that involve a number of risks and uncertain
Slide 3: InfuSystem at a Glance
InfuSystem at a Glance 2013 9-Month Financials Company Overview Innovative provider and supplier of infusion services Market leader in oncology home infusion with 40,000 patients a year – 25 Year business model World-class pump rentals and service to providers, manufacturers, and other rental compan
Slide 4: Full Line Multi-Therapy & Multi-Point Offering
Full Line Multi-Therapy & Multi-Point Offering Provider Payor Device & Pharma Manufacturer, Distributor, GPO, ACO Partners Patient
Slide 5: Positioned For Growth
Positioned For Growth Strategy Leadership Market Trends • InfuSystem is uniquely positioned to take advantage of market trends •Leadership can now focus on running a business for first time in over a year •Transformational strategy is developed and being implemented
Slide 6: InfuSystem Niche – Extension of Clinic to Home
InfuSystem Niche – Extension of Clinic to Home Ambulatory Home Infusion TPP Payor Contracts 25-year old business model in DME billing At home, at work, at play, all while receiving the drug High satisfaction scores 24/7 on-call oncology nurses Proven outcomes with continuous home infusion Oncology,
Slide 7: US Population Growing, Aging, Cancer
US Population Growing… Aging Population Stats Cancer Colo-rectal At-risk lifestyles persist (red, processed meats) Growth in all types of cancers 1,650,000 new cancer cases in 2013 Can be treated effectively by continuous infusion rd most common in US and Worldwide 9% of all new cases 145,000 new ca
Slide 8: TPP Pump Return on Investment
TPP Pump Return on Investment Average Cost ~$1,500/pump Pump Lifespan 15 years Average Monthly Revenue ~$300/pump Lifetime Revenue/Pump Approx. ~$20,000+
Slide 9: Increasing Therapy Offerings to Payors
Increasing Therapy Offerings to Payors Payor Special Disease States Surgery Infectious Disease Oncology
Slide 10: Rentals, Sales & Service to Providers
Rentals, Sales & Service to Providers Pump Rentals, Sales and Asset Management Preventative Maint. Repair Pump Experts Direct sales, rental, and lease of device and supplies in US and Canada Pump Broker Expertise – ability to acquire and dispose of CAP EX in cost effective way Asset management, rent
Slide 11: Provider Offering Infusion to All Points of Care
Provider Offering Infusion to All Points of Care Oncology Acute Care Emergency Services Long Term Care Home Infusion
Slide 12: Continued Revenue Diversification
Continued Revenue Diversification 2009 Revenues $39M 2012 Revenues $59M
Slide 13: Connectivity through EMR, Web Portal and System Interface
Connectivity through EMR , Web Portal and System Interface
Slide 14: Connectivity through EMR, Web Portal and System Interface
Connectivity through EMR , Web Portal and System Interface Electronic Data Exchange Interface Effects Customer investment in interface makes for sticky relationships. Ties customer to InfuSystem.
Slide 15: For Faster Turnaround and Improved Utilization
For Faster Turnaround and Improved Utilization InfuSystem Distribution Kansas City Service Center Madison Heights Service Center Future New Jersey Service Center Future Atlanta Service Center Los Angeles Area Service Center Houston Service Center Toronto Canada Service Center High-density Metro Mark
Slide 16: Where Does This Get INFU In Three Years?
Where Does This Get INFU In Three Years ? Aging Population and Cancer Growth More Patients Home IV , Commercial Pay Recognizing Value, CMS Competitive Bidding Peripheral Nerve Block and Smart Pump Growth Revenue Growth in High Single Digits Through
Slide 17: InfuSystem: Infusion Made Easy
CInfuSystem INFUSION MADE EASY.
Slide 18: Financial Overview
Financial Overview Revenues Adjusted EBITDA Free Cash Flow (1) Unrestricted Liquidity (1) Free Cash Flow = Adjusted EBITDA less CapEx and Purchases of Medical Equipment $38,964 $47,229 $54,637 $58,828 $56,793 $60,137 $30m $40m $50m $60m $70m FY2009 FY2010 FY2011 FY2012 9M 2012 Annualized 9M 2013 Ann
Slide 19: Uses of Free Cash Flow, Total Debt, Medical Equipment
Uses of Free Cash Flow Total Debt PP&E and Medical Equipment in Service (at cost) (1) Free Cash Flow = Adjusted EBITDA less CapEx and Purchases of Medical Equipment $24,141 $32,197 $29,127 $31,268 $28,466 $28,328 $27,619 $20m $25m $30m $35m FY2009 FY2010 FY2011 FY2012 1Q 2013 2Q 2013 3Q 2013 Debt De
Slide 20: InfuSystem: Infusion Made Easy
CInfuSystem INFUSION MADE EASY.
Slide 21: Positioned For Growth
Positioned For Growth Market Trends Leadership Strategy • InfuSystem is uniquely positioned to take advantage of market trends •Leadership can now focus on running a business for first time in over a year •Transformational strategy is developed and being implemented
Slide 22: Thank You for Your Interest!
Thank You for Your Interest! IR Contact Info: The Dilenschneider Group 212-922-0900 Rob Swadosh, rswadosh@dgi-nyc.com Patrick Malone, pmalone@dgi-nyc.com
Slide 23: InfuSystem: Infusion Made Easy
CInfuSystem INFUSION MADE EASY.
Slide 24: Compelling Value Proposition
Compelling Value Proposition “ONE-STOP SHOP” SERVICE & REPAIRS CONVENIENCE & FLEXIBILITY PRE-OWNED EQUIPMENT EXPERTISE Complementary core competencies allow InfuSystem to offer superior selection, flexibility, pricing and services In-House Service & Repairs Convenience & Flexibility Pre-Owned Equipm
Slide 25: Payor & Customer Mix
Payor & Customer Mix Leading Cancer Institution Customers Revenue by Payor (FY2012) InfuSystem has strong relationships with the largest third-party payors and the leading cancer institutions 9 of 10 of the Top Ten Cancer Treatment Centers Medicare and Medicaid 37% BCBS 19% Commercial 38% High diver
Slide 26: Competitive Landscape
Competitive Landscape Market Share for Oncology Continuous Infusion InfuSystem 32% Home Infusion Providers 32% Facility Owned Pumps 11% Competitor DME Providers 10% Captive Health Plan 14% InfuSystem measures its market share not in terms of the number of practices, but the pool of addressable patie
Slide 27: Direct Payor Business Model
Direct Payor Business Model Service & Repair Products InfuSystem sells, rents and finances a wide variety of new and used large volume and ambulatory pumps InfuSystem services and repairs both its own fleet of pumps and many types of other movable medical equipment InfuSystem’s Direct Payor business
Slide 28: Direct Payor Offerings
Direct Payor Offerings Pre-Owned & New Pumps from Top Manufacturers Leading Provider of New and Pre-Owned Pumps Full Spectrum of Ownership Options for Customers Rental Sales Asset Management InfuSystem offers new pumps from top brands Broker-dealer trading desk In addition, over 70 models and versio
Slide 29: Medical Equipment Service & Repair
Medical Equipment Service & Repair In addition to supporting and repairing InfuSystem’s in-house fleet, the Company certifies, recalibrates, repairs and services a variety of infusion pumps Pumps require scheduled maintenance and calibration in accordance with manufacturer’s specifications and regul
Slide 30: Ambulatory Pump Rental Fleet
Ambulatory Pump Rental Fleet Annual Rental Revenue per $1 Rental Fleet Cost (“Revenue Ratio”) With over 26,000+ pumps in TPP Rental Fleet, InfuSystem maintains the largest fleet of ambulatory infusion pumps in the industry DPP Rental Fleet has over 20,000 pumps The Company has a complete inventory o
Slide 31: Competitive Bidding Overview
Competitive Bidding Overview Competitive Bidding Overview InfuSystem’s Response to Competitive Bidding CMS Competitive Bidding “Target” Timetable Spring 2012 08/16/12 10/15/12 12/14/12 10/1/13 12/31/13 01/01/14 InfuSystem was not involved in Round 1 nor Round 2 of Competitive Bidding CMS announced a
Slide 32: Slide 32
Slide 33: Continued Revenue Diversification
Continued Revenue Diversification 2009 Revenue 70% 26% 1% 1% 2%
Slide 34: Continued Revenue Diversification
Continued Revenue Diversification 2009 Revenues $39M 2012 Revenues $59M 70% 26% 1% 1% 2% 51% 23% 13% 4% 9%
Slide 35: Summary Balance Sheet
Summary Balance Sheet ($000's) 12/31/09 12/31/10 12/31/11 12/31/12 3/31/13 6/30/13 9/30/13 ASSETS Current Assets: Cash and cash equivalents 7,750 $ 5,014 $ $ 2,326 $ $ $ $ Account receivable - total, net of allowance 5,517 $ 6,679 $ 7,448 $ 8,511 $ 9,570 $ 9,440 $ 9,291 $ Inventory $ 1,699 $ 1,309 $
Slide 36: Cash Flow
Cash Flow ($000's) FY2009 FY2010 FY2011 FY2012 9 Mo 2012 9 Mo 2013 OPERATING ACTIVITIES Net Income $ (1,852) $ (45,443) $ (1,489) $ Adjustments: Provision for doubtful accounts 4,006 $ 4,515 $ 4,099 $ 5,251 $ Depreciation 4,122 $ 5,357 $ 6,386 $ 5,668 $ Loss on disposal of pumps $ $ 1,731 $ $ Amorti